Welcome to our dedicated page for Tourmaline Bio news (Ticker: TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Tourmaline Bio Inc (TRML) is a clinical-stage biotechnology company advancing novel therapies for inflammatory diseases through targeted IL-6 pathway modulation. This news hub provides investors and researchers with essential updates on the company's progress, including developments for its lead candidate pacibekitug (TOUR006).
Access comprehensive coverage of clinical trial milestones, regulatory updates, and strategic partnerships. Our curated news collection offers timely insights into Tourmaline Bio's innovative approach to autoimmune treatment and cardiovascular inflammation research.
Key updates include progress in flagship programs targeting atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED), along with financial disclosures and scientific presentations. All content is verified through primary sources to ensure accuracy and relevance.
Bookmark this page for streamlined access to Tourmaline Bio's latest developments. Check regularly for updates on clinical data readouts, and expert analyses of the company's position in the immunology therapeutics landscape.
Tourmaline Bio announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Robinson has been with Tourmaline since last summer and has served as the Interim CFO and Treasurer since October 2023. He played a key role in Tourmaline's growth, including a reverse merger in October 2023 and a $172.5 million public offering in January 2024. Robinson brings nearly 15 years of biotech finance and operations experience, having worked at Korro Bio, Jounce Therapeutics, and Merrimack Pharmaceuticals. He holds a B.S. in Management and an M.S. in Accounting from Boston College and is a CPA.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company, announced that its CEO, Sandeep Kulkarni, will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 6, 2024, at 2:30 pm ET. A live webcast and replay will be available on the Tourmaline Bio website.
Tourmaline Bio has dosed the first patient in its Phase 2 TRANQUILITY trial for TOUR006, a monoclonal antibody targeting IL-6 to treat atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular conditions. This randomized, double-blind, placebo-controlled trial involves patients with high inflammatory risk and chronic kidney disease. The trial aims to assess the drug's safety, pharmacokinetics, and pharmacodynamics, with results anticipated in the first half of 2025. If successful, TOUR006 could advance to Phase 3 by 2025, offering quarterly subcutaneous dosing and potentially positioning itself as a best-in-class treatment for ASCVD and related conditions.
Tourmaline Bio, Inc. reported its Q1 2024 financial results and recent business highlights. Initiatives include a Phase 2 trial for ASCVD and TED, a successful public offering, and $350.3 million in cash reserves. The company aims to improve the lives of patients with immune and inflammatory diseases.
FAQ
What is the current stock price of Tourmaline Bio (TRML)?
What is the market cap of Tourmaline Bio (TRML)?
